Hepion Pharmaceuticals, Inc. (HEPA) stock
HEPAOTCPharmaceutical PreparationsFiscal year ends December 31Also trades as CTRVP
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q/A on Nov 17, 2026Score 1/30
$0.10−0.00 (-1.45%)
Close on Oct 19, 2026Market cap $7.26MP/E –Yield –
Hepion Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
Hepion Pharmaceuticals's R&D Expenses for the twelve months ending Sep 30, 2026 was $255.57K. For fiscal 2025 it was $445.51K, down 96.2% from the year before. Over ten years it grew 3.6% a year on average. The highest annual figure on record is $35.64M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $445.51K | -96.2% |
| FY2024 | Dec 31, 2024 | $11.85M | -66.8% |
| FY2023 | Dec 31, 2023 | $35.64M | +7.1% |
| FY2022 | Dec 31, 2022 | $33.27M | +63.1% |
| FY2021 | Dec 31, 2021 | $20.40M | +70.0% |
| FY2020 | Dec 31, 2020 | $12.00M | +276.8% |
| FY2019 | Dec 31, 2019 | $3.18M | -76.7% |
| FY2017 | Jun 30, 2017 | $13.65M | -9.1% |
| FY2016 | Jun 30, 2016 | $15.02M | +78.7% |
| FY2015 | Jun 30, 2015 | $8.40M | +2574.2% |
| FY2014 | Jun 30, 2014 | $314.25K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ3 2026 | Sep 30, 2026 | $134.65K | – |
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | $50.92K | -88.0% |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | $70.00K | +214.8% |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | $0 | -100.0% |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | $0 | -100.0% |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | $423.28K | -83.3% |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | $22.24K | -99.6% |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | $2.76M | -67.6% |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | $7.14M | -39.9% |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | $2.54M | -74.1% |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | $5.44M | -27.6% |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | $8.52M | +48.4% |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | $11.88M | -24.3% |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | $9.80M | +127.3% |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | $7.52M | +8.8% |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | $5.74M | -1.0% |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | $15.70M | +275.1% |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | $4.31M | +23.2% |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | $6.91M | +163.0% |
| Q3 FY2021CQ3 2021 | Sep 30, 2021 | $5.80M | +53.3% |
| Q2 FY2021CQ2 2021 | Jun 30, 2021 | $4.19M | +41.9% |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | $3.50M | +32.7% |
| Q4 FY2020CQ4 2020 | Dec 31, 2020 | $2.63M | +146.9% |
| Q3 FY2020CQ3 2020 | Sep 30, 2020 | $3.78M | +346.9% |
| Q2 FY2020CQ2 2020 | Jun 30, 2020 | $2.95M | +290.4% |
| Q1 FY2020CQ1 2020 | Mar 31, 2020 | $2.64M | +409.1% |
| Q4 FY2019CQ4 2019 | Dec 31, 2019 | $1.06M | -67.4% |
| Q3 FY2019CQ3 2019 | Sep 30, 2019 | $846.45K | -71.3% |
| Q2 FY2019CQ2 2019 | Jun 30, 2019 | $755.66K | -82.5% |
| Q1 FY2019CQ1 2019 | Mar 31, 2019 | $518.04K | -83.4% |
| Q4 FY2017CQ2 2017 | Jun 30, 2017 | $3.26M | -19.0% |
| Q3 FY2017CQ1 2017 | Mar 31, 2017 | $2.94M | -7.6% |
| Q2 FY2017CQ4 2016 | Dec 31, 2016 | $4.32M | +6.8% |
| Q1 FY2017CQ3 2016 | Sep 30, 2016 | $3.13M | -16.9% |
| Q4 FY2016CQ2 2016 | Jun 30, 2016 | $4.02M | +12.1% |
| Q3 FY2016CQ1 2016 | Mar 31, 2016 | $3.19M | – |
| Q2 FY2016CQ4 2015 | Dec 31, 2015 | $4.04M | – |
| Q1 FY2016CQ3 2015 | Sep 30, 2015 | $3.77M | – |
| Q4 FY2015CQ2 2015 | Jun 30, 2015 | $3.59M | – |
See a number that looks wrong?